Jones Kenneth T. - 08 Aug 2023 Form 3 Insider Report for Zynerba Pharmaceuticals, Inc.

Role
Officer
Signature
/s/ Albert P. Parker, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
08 Aug 2023
Net transactions value
$0
Form type
3
Filing time
15 Aug 2023, 16:05:52 UTC
Next filing
14 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ZYNE Common Stock 79,025 08 Aug 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ZYNE Stock Option (right to buy) 08 Aug 2023 Common Stock 35,000 $20.02 Direct F1
holding ZYNE Stock Option (right to buy) 08 Aug 2023 Common Stock 24,000 $11.71 Direct F1
holding ZYNE Stock Option (right to buy) 08 Aug 2023 Common Stock 20,000 $3.65 Direct F1
holding ZYNE Stock Option (right to buy) 08 Aug 2023 Common Stock 22,500 $5.05 Direct F2
holding ZYNE Stock Option (right to buy) 08 Aug 2023 Common Stock 20,000 $3.58 Direct F3
holding ZYNE Stock Option (right to buy) 08 Aug 2023 Common Stock 21,250 $2.41 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option is fully vested and immediately exercisable.
F2 The stock option vests 25% on January 30, 2021, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date.
F3 The stock option vests 25% on January 21, 2022, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date.
F4 The stock option vests 25% on January 26, 2023, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date.

Remarks:

Vice President, Corporate Controller and Interim Chief Financial Officer; Exhibit List - Exhibit 24 - Power of Attorney